PRRT2 and cancer: Of these, specific inhibitors of PI3Kp110β [181] and PKC [182,183,184], besides tyrosine kinase inhibitors widely recommended against cancer, like SYK, BTK, those of the Src family [185,186], agents antagonizing integrin αIIbβ3 by specifically targeting the active form of the receptor [187,188] or the outside-in signaling [189,190], a fusion protein combining the extracellular domain of CD39, and a single-chain antibody (Targ-CD39) that specifically detects activated integrin αIIbβ3 [191] have emerged in recent years.